research Abstracts
Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in Partial Response Despite Continuous Vismodegib Treatment
Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.
research Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma
Axitinib treatment turned a man's grey hair back to black.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
research Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
Adalimumab helped control a child's severe eye disease when other treatments failed.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
research Clinical perspective on management of key adverse events with sacituzumab govitecan
Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
research Dermpath & Clinic: Telangiectasia macularis eruptiva perstans
Brodalumab is more effective than ustekinumab in treating psoriasis.
research Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
research Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Vorasidenib-Induced Trichomegaly and Hypertrichosis: a New Side Effect in a Patient with Diffuse Astrocytoma
Vorasidenib can cause unusual hair growth.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
research Anais do II Congresso Nacional Acadêmico de Dermatologia
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.